19.01.2017
Evotec AG DE0005664809
DGAP-News: EVOTEC ENTERS INTO AN INTEGRATED DRUG DISCOVERY COLLABORATION WITH ASAHI KASEI PHARMA (JAPAN)
DGAP-News: Evotec AG / Key word(s): Alliance
EVOTEC ENTERS INTO AN INTEGRATED DRUG DISCOVERY COLLABORATION WITH ASAHI
KASEI PHARMA (JAPAN)
19.01.2017 / 07:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany, 19 January 2017:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
announced it has entered into an integrated drug discovery collaboration on
an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned
subsidiary of Asahi Kasei Corporation, Tokyo, Japan.
Under the terms of the agreement, Evotec will apply its integrated drug
discovery platform including medicinal chemistry, computational chemistry
and in vitro pharmacology to optimise hit compounds identified and selected
from the Evotec compound library collection through a recent successful
high-throughput screening campaign executed at Evotec.
Dr Mario Polywka, Chief Operating Officer of Evotec, stated: "We are
delighted to expand our collaboration with Asahi Kasei Pharma into a fully
integrated drug discovery project. Evotec operates one of the most
comprehensive ion channel platforms in the industry and this collaboration
represents further validation of the strength of this platform and the
library screened. We look forward to working closely with our colleagues at
Asahi Kasei Pharma."
No financial details were disclosed.
ABOUT ASAHI KASEI
Asahi Kasei Pharma Corporation, headquartered in Tokyo, Japan, is a
research-based health care innovator that discovers, develops,
manufactures, and markets pharmaceuticals and diagnostic products. Asahi
Kasei Pharma is a wholly owned business unit of Asahi Kasei Corporation, a
US$ 18 billion technology company that provides innovative, science-based
solutions to a diverse range of markets including health care, chemicals
and fibers, housing and construction materials, and electronics. For more
information, please visit the Asahi Kasei Corporation website at
www.asahi-kasei.co.jp.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery
solutions, covering all activities from target-to-clinic to meet the
industry's need for innovation and efficiency in drug discovery (EVT
Execute). The Company has established a unique position by assembling
top-class scientific experts and integrating state-of-the-art technologies
as well as substantial experience and expertise in key therapeutic areas
including neuroscience, diabetes and complications of diabetes, pain and
inflammation, oncology and infectious diseases. On this basis, Evotec has
built a broad and deep pipeline of more than 70 partnered product
opportunities at clinical, pre-clinical and discovery stages (EVT
Innovate). Evotec has established multiple long-term discovery alliances
with partners including Bayer, CHDI, Sanofi or UCB and development
partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's
disease, with Sanofi in the field of diabetes and with Pfizer in the field
of tissue fibrosis and with Celgene in the field of neurodegenerative
diseases. For additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
19.01.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
537581 19.01.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT